Berman David M, serving as Head of R&D, has been a persistent seller of Immunocore Holdings plc (IMCR) stock over the past year, with SEC Form 4 filings revealing a clear disposition pattern. Across 40 transactions, all concentrated in the single ticker, Berman has generated approximately $18.4 million in total sale value without a single open-market purchase. The recent activity, spanning September 2025 through February 2026, shows 14 open-market sales (code S) paired with corresponding option exercises (code M), a structure that suggests the sales are tied to the conversion of existing equity awards rather than discretionary accumulation.
The transaction sizes vary considerably, from small dispositions of roughly $4,000 to substantial block sales exceeding $2.7 million. Notable large sales occurred on November 26, 2025 ($2.78 million), September 30, 2025 ($2.18 million), and December 4, 2025 ($1.26 million), each accompanied by option exercises of comparable magnitude. More recent activity includes a $192,968 sale on February 18, 2026, following an option exercise the prior day, and a series of smaller sales in late November 2025 ranging from $4,000 to $721,341. The pattern of exercising options and immediately selling shares is consistent across all filings, with no evidence of open-market purchases (code P) or acquisitions outside of compensation-related grants.
The directional bias is unambiguous: Berman has been a net seller throughout the entire reporting period, with zero buy-side activity against $18.4 million in sales. The recurring pairing of option exercises with same-day or next-day sales indicates a systematic approach to liquidating vested equity, though the irregular timing and varying sizes suggest the sales are not on a fixed schedule. This activity, while substantial in aggregate, reflects a consistent reduction of IMCR exposure by a senior executive rather than any opportunistic trading pattern.
AI-assisted summary